



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request
Ein Cyf / Our Ref: 22-G-019

Please note that we have provided this information for the period January to June 2022

You asked:

1. Does your Health Board treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?

Yes

2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?

10 patients treated with a new diagnosis of DLBCL. This does not include patients with an existing diagnosis.

3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

| | |
|--|---|
| R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) | 19 |
| R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) | Nil |
| Other immuno-chemotherapy | 8 |
| Other chemotherapy | 8 |
| Stem cell transplant or bone marrow transplant (autologous or allogeneic) | SBUHB does not hold this information. These patients are treated by Cardiff & Vale UHB. |
| Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment | <5* |
| Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only | Nil |



| | |
|--------------------------|---|
| Tisagenlecleucel | SBUHB does not hold this information. These patients are treated by Cardiff & Vale UHB. |
| Axicabtegene ciloleucel | SBUHB does not hold this information. These patients are treated by Cardiff & Vale UHB. |
| Lisocabtagene maraleucel | N/A |

4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:

- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

0 patients

- **CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel)**

<5* patients

5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

No

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

